Cibus (NASDAQ:CBUS) Now Covered by Analysts at Alliance Global Partners

Investment analysts at Alliance Global Partners assumed coverage on shares of Cibus (NASDAQ:CBUS) in a note issued to investors on Monday, Marketbeat.com reports. The firm set a “buy” rating and a $25.00 price target on the stock. Alliance Global Partners’ price target would suggest a potential upside of 148.26% from the company’s previous close.

CBUS has been the topic of a number of other research reports. Canaccord Genuity Group restated a “buy” rating and issued a $22.00 target price on shares of Cibus in a research report on Friday, July 19th. Canaccord Genuity Group upgraded shares of Cibus to a “strong-buy” rating in a research report on Friday, July 19th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Cibus in a report on Friday, May 10th.

Cibus Trading Down 1.8 %

NASDAQ CBUS opened at $10.07 on Monday. The firm has a market capitalization of $217.01 million, a price-to-earnings ratio of -0.55 and a beta of 1.91. The firm’s 50 day simple moving average is $10.58 and its 200 day simple moving average is $15.47. Cibus has a 1 year low of $7.41 and a 1 year high of $23.18.

Cibus (NASDAQ:CBUS) last issued its earnings results on Thursday, May 9th. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.11). Cibus had a negative net margin of 12,313.28% and a negative return on equity of 23.33%. The company had revenue of $0.55 million during the quarter, compared to analyst estimates of $0.40 million. During the same quarter in the prior year, the business earned ($5.45) EPS. On average, equities research analysts forecast that Cibus will post -3.22 earnings per share for the current year.

Hedge Funds Weigh In On Cibus

A number of hedge funds have recently modified their holdings of the business. Gladius Capital Management LP acquired a new position in shares of Cibus during the fourth quarter worth $56,000. Indie Asset Partners LLC lifted its holdings in shares of Cibus by 30.1% during the fourth quarter. Indie Asset Partners LLC now owns 16,929 shares of the company’s stock worth $332,000 after purchasing an additional 3,921 shares during the period. Cerity Partners LLC bought a new position in Cibus during the fourth quarter worth $323,000. Vanguard Group Inc. raised its stake in Cibus by 3.7% during the first quarter. Vanguard Group Inc. now owns 721,945 shares of the company’s stock worth $16,215,000 after buying an additional 26,017 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new position in Cibus during the second quarter worth $529,000. Institutional investors and hedge funds own 33.81% of the company’s stock.

Cibus Company Profile

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.